ULTRAGENYX PHARMACULTRAGENYX PHARMACULTRAGENYX PHARMAC

ULTRAGENYX PHARMAC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.19 B‬CHF
−7.240CHF
‪−510.75 M‬CHF
‪365.61 M‬CHF
‪77.02 M‬
Beta (1Y)
1.44

About Ultragenyx Pharmaceutical Inc.

CEO
Emil D. Kakkis
Headquarters
Novato
Employees (FY)
‪1.28 K‬
Founded
2010
FIGI
BBG00LVGHPH1
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of UP0 is 40.517 CHF — it has decreased by 7.44% in the past 24 hours. Watch ULTRAGENYX PHARMAC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ULTRAGENYX PHARMAC stocks are traded under the ticker UP0.
ULTRAGENYX PHARMAC is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
UP0 stock is 8.04% volatile and has beta coefficient of 1.44. Track ULTRAGENYX PHARMAC stock price on the chart and check out the list of the most volatile stocks — is ULTRAGENYX PHARMAC there?
UP0 earnings for the last quarter are −1.83 CHF per share, whereas the estimation was −1.58 CHF resulting in a −16.19% surprise. The estimated earnings for the next quarter are −1.52 CHF per share. See more details about ULTRAGENYX PHARMAC earnings.
ULTRAGENYX PHARMAC revenue for the last quarter amounts to ‪98.18 M‬ CHF despite the estimated figure of ‪104.68 M‬ CHF. In the next quarter revenue is expected to reach ‪111.57 M‬ CHF.
Yes, you can track ULTRAGENYX PHARMAC financials in yearly and quarterly reports right on TradingView.
UP0 stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in ULTRAGENYX PHARMAC price.
UP0 net income for the last quarter is ‪−153.98 M‬ CHF, while the quarter before that showed ‪−103.72 M‬ CHF of net income which accounts for −48.46% change. Track more ULTRAGENYX PHARMAC financial stats to get the full picture.
Today ULTRAGENYX PHARMAC has the market capitalization of ‪3.24 B‬, it has decreased by 9.12% over the last week.
No, UP0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, UP0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ULTRAGENYX PHARMAC stock right from TradingView charts — choose your broker and connect to your account.
UP0 reached its all-time high on Sep 1, 2022 with the price of 46.787 CHF, and its all-time low was 40.517 CHF and was reached on Sep 27, 2022. View more price dynamics on UP0 chart.
See other stocks reaching their highest and lowest prices.
As of May 7, 2024, the company has ‪1.28 K‬ employees. See our rating of the largest employees — is ULTRAGENYX PHARMAC on this list?
We've gathered analysts' opinions on ULTRAGENYX PHARMAC future price: according to them, UP0 price has a max estimate of 126.74 CHF and a min estimate of 42.55 CHF. Watch UP0 chart and read a more detailed ULTRAGENYX PHARMAC stock forecast: see what analysts think of ULTRAGENYX PHARMAC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ULTRAGENYX PHARMAC EBITDA is ‪−496.29 M‬ CHF, and current EBITDA margin is −125.09%. See more stats in ULTRAGENYX PHARMAC financial statements.